INTRODUCTION
============

Endometriosis is a gynecological disorder affecting nearly 10% of the female population during their reproductive age \[[@b1-alm-2020-40-5-390]\]. It is characterized by the growth of endometrial stroma and glands at extra-uterine sites. It is commonly associated with localized inflammation in the pelvis \[[@b2-alm-2020-40-5-390]\] and increased growth of endometriotic lesions in the presence of oxidative stress (OS) \[[@b3-alm-2020-40-5-390]\]. OS is characterized by increased intracellular levels of reactive oxygen species (ROS). ROS provoke the up-regulation of inflammatory cytokine molecules through distinct molecular mechanisms. They regulate activation of nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB), which is associated with immune and inflammatory responses \[[@b4-alm-2020-40-5-390]\]. The link between NF-κB activation and inflammation in endometriosis has been demonstrated \[[@b5-alm-2020-40-5-390], [@b6-alm-2020-40-5-390]\]. In recent years, the possible role of ROS in regulating the mediators of inflammation \[[@b7-alm-2020-40-5-390]\], angiogenesis \[[@b8-alm-2020-40-5-390]\] and matrix degradation \[[@b9-alm-2020-40-5-390]\] has received increasing attention.

Cytokines, known as important mediators of intercellular communication, are also produced by the endometriotic implants. Cytokines appear to play vital roles in the development and progression of endometriosis and associated infertility \[[@b5-alm-2020-40-5-390]\]. Aberrant expression of cytokines may also induce extracellular matrix (ECM) degradation \[[@b8-alm-2020-40-5-390], [@b9-alm-2020-40-5-390]\]. Matrix metalloproteinases (MMPs) are reported to play a pivotal role in establishing ectopic endometrial growth in endometriosis. The endometrial expression of MMPs is regulated by different growth factors, steroid hormones, and cytokines \[[@b12-alm-2020-40-5-390]\]. For endometrial tissue implantation and growth to occur in ectopic sites, the tissue must first attach itself to the host tissue, then invade it by obtaining its own blood supply from the local vasculature \[[@b13-alm-2020-40-5-390]\]. This implantation of ectopic endometrial fragments is based on neovascularization to guarantee a supply of oxygen and essential nutrients \[[@b14-alm-2020-40-5-390]\]. Vascular endothelial growth factor (VEGF) has emerged as a chief regulator of normal angiogenesis and pathological neovascularization in endometriosis \[[@b15-alm-2020-40-5-390]--[@b17-alm-2020-40-5-390]\].

There is overwhelming evidence supporting that inflammation, angiogenesis, ECM degradation, and OS play the key roles in the pathogenesis and progression of endometriosis \[[@b15-alm-2020-40-5-390], [@b18-alm-2020-40-5-390]\]. However, the effect of the interplay among these factors on disease pathogenesis remains unclear. Previously, we demonstrated the role of OS in endometriosis \[[@b19-alm-2020-40-5-390]\]. The present study is an extension of our previous work, in which we showed that several OS markers, including catalase, lipid peroxidation, superoxide dismutase, total antioxidant capacity, glutathione, and advanced oxidation protein products, are dysregulated in patients with endometriosis. Thus, we performed a comprehensive investigation of the molecules involved in inflammation, angiogenesis, and ECM degradation in patients with endometriosis to study their role in disease pathogenesis. In addition, we identified the most important molecule involved in endometriosis pathogenesis. Finally, we propose a model explaining the interplay among various molecules in the disease.

MATERIALS AND METHODS
=====================

Patient selection and sample collection
---------------------------------------

This nested case-control retrospective study was performed from August 2016 to July 2018. The necessary ethical approval was obtained from the Institutional Scientific and Ethical Committee of National Institute of Technology, Arunachal Pradesh, India \[Proposal\# NIT(A.P)/R&D/Project/11-12/1/Vol.2/IEC-02\] prior to commencing this study. Written informed consent was obtained from the patients prior to blood collection. Blood samples (N=80) were collected at Pratiksha Hospital, Guwahati, Assam, India, from women with endometriosis, confirmed by diagnostic laparoscopy followed by a biopsy. Samples (N=80) were also collected from women with tubal factor infertility who served as controls. Tubal factor infertility corresponds to women undergoing salpingectomy for ectopic pregnancy or proximal tubal obstruction due to low-grade infection or fimbrial occlusion with or without mild peritubular adhesions. The women included in the study did not receive any medical or hormonal treatment during the last three months. Moreover, women with a prior history of any gynecological surgery, including chocolate cyst, lower pelvic and abdominal surgery, with other possible causes of pain or pelvic pathology, including pelvic tuberculosis, were excluded from the study. Venous blood samples (10 mL) were collected in sterile vacutainers by medical practitioners during the daytime from patients in fasting state and in their early follicular phase, as described previously \[[@b19-alm-2020-40-5-390], [@b20-alm-2020-40-5-390]\]. The collected blood samples were allowed to clot and centrifuged at 2,000×*g* for 10 minutes at 4°C. The supernatant serum samples were transferred to sterile tubes and stored at −80°C till further analysis of various cytokines, angiogenic factors, matrix-degrading proteases and their inhibitors. Anthropometric parameters such as age, body mass index (BMI), and estrogen levels were obtained from the patient data sheet. Serum estrogen level was measured using the Estradiol E2 Human ELISA Kit (Abcam, Cambridge, UK).

Measurement of various cytokines, angiogenic molecules, and MMPs
----------------------------------------------------------------

The levels of interleukin (IL)-1β, tumor necrosis factor-alpha (TNF-α), interferon-gamma (IFN-γ), transforming growth factor-beta (TGF-β1), IL-4, −10, −2, −6, −8, VEGF, MMP-2, −9, tissue inhibitor of metalloproteinase (TIMP)-1, −2, and cyclooxygenase-2 (COX-2) were evaluated using ELISA, as described previously \[[@b7-alm-2020-40-5-390]\]. Briefly, human IL-1β, TNF-α, IFN-γ, and IL-10, −2, −4, −6, and −8 levels were measured using the corresponding ELISA kits (R&D Systems, Minnesota, USA), whereas TGF-β1, MMP-2, −9, TIMP-1, −2, and COX-2 levels were determined using an anti-human Rb polyclonal antibody against TGF-β1, MMP-2, −9, TIMP-1, −2, and COX-2 (Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA), respectively. VEGF was determined using an anti-human Rb polyclonal antibody against VEGF (Santa Cruz Biotechnology, Inc.), employing a quantitative indirect enzyme immunoassay technique. All assays and calibrations were performed in triplicate. In cases of very high or low results, the measurements were repeated. The intra- and inter-assay variability were, respectively: 2.5% and 3.11% for IL-1β, 2.7% and 5.3% for TNF-α, 3.2% and 4.3% for IFN-γ, \<7% and \<8% for TGF-β1, 3.7% and 2.6% for IL-4, 2.1% and 5.8% for IL-10, 3.1% and 3.3% for IL-2, 4.1% and 7.9% for IL-6, 4% and 3.2% for IL-8, 5.3% and 7.6% for VEGF, 6% and \<7% for MMP-2, \<5% and \<7% for MMP-9, \<5% and \<8% for TIMP-1, \<5% and \<6% for TIMP-2, and \<8% and \<12% for COX-2.

Measurement of NF-κB in peripheral blood mononuclear cells (PBMCs)
------------------------------------------------------------------

To establish the role of NF-κB in the pathogenesis of endometriosis, its expression in PBMCs was investigated. After immediate collection of venous blood samples, PBMCs were isolated as reported previously \[[@b21-alm-2020-40-5-390]\]. Next, 10 mL of peripheral whole blood was loaded with 3.8% sodium citrate (9:1; v/v) onto a Ficoll-Paque Plus gradient (GE17-1440-02, Sigma, India). The mix was then centrifuged for 30 minutes at 500×*g* at room temperature. The band containing PBMCs was separated, and the cells were washed three times in phosphate-buffered saline (PBS) solution, pH 7.4. The cells were then examined under a microscope and counted independently by two investigators. The number of the cells was fixed to 1×10^6^ PBMCs/mL. Measurement of NF-κB in PBMCs was performed as described by Ichiyama, *et al.* \[[@b22-alm-2020-40-5-390]\]. Briefly, the cells were labeled with human specific mouse NF-κB antibodies (nuclear-localized signal p-50 and p-65; sc-8414 and sc-8008, Santa Cruz Biotechnology, Inc.). Cells were then tagged with fluorescein isothiocyanate-conjugated rat anti-mouse IgG3 monoclonal antibody (Pharmingen, San Diego, CA, USA). After washing, the cells were fixed with 1% paraformaldehyde in PBS and subjected to flow cytometry. Mean fluorescence data acquisition was performed in Cell Quest Pro software attached to a fluorescence activated cell sorter (FACS Calibre, M/S Becton, Dickinson and Company, Franklin Lakes, New Jersey, USA). All experiments were performed in triplicate.

Statistical analysis
--------------------

Data analysis using t-tests was performed with Key Plot version 2.0 beta 13 (<https://kyplot.software.informer.com/2.0/>) and GraphPad QuickCalcs, (GraphPad Software Inc., San Diego, CA, USA) following data normalization. Statistical significance was defined as *P*≤0.05. All data are presented as mean ± SD. Multivariate statistical analysis, including principal-component analysis (PCA) and partial least square discriminate analysis (PLS-DA), was performed using SIMCA 15.0.2 (Umetrics, Malmö, Sweden). PCA, an unsupervised modeling approach, was used to identify a general trend in the samples. Supervised modeling, PLS-DA, was used to identify the most relevant variable responsible for the separation of endometriosis samples from controls. The quality of the PLS-DA model was determined using R2 (goodness of fit) and Q2 (goodness of prediction) values. Furthermore, the model was cross-validated by permutation test statistics using 100 different permuted models.

RESULTS
=======

The demographic data ([Table 1](#t1-alm-2020-40-5-390){ref-type="table"}) did not show any significant difference in age and BMI between women with endometriosis and the controls. Serum estrogen levels were significantly higher in patients with endometriosis. [Table 2](#t2-alm-2020-40-5-390){ref-type="table"} summarizes the expression levels of various cytokines. All cytokine levels were found to be significantly higher in women with endometriosis than in controls. The level of VEGF was also significantly higher in patients with endometriosis ([Table 2](#t2-alm-2020-40-5-390){ref-type="table"}). While MMP-2, −9 and COX-2 levels were significantly higher, TIMP-1 and −2 levels were significantly lower in women with endometriosis than in controls ([Table 2](#t2-alm-2020-40-5-390){ref-type="table"}).

As shown in [Fig. 1](#f1-alm-2020-40-5-390){ref-type="fig"}, NF-κB (p-50 and p-65) expression was increased in patients with endometriosis than in controls. Finally, multivariate statistical analysis was used to identify the most significant variable responsible for discrimination of endometriosis cases from the control group ([Fig. 2](#f2-alm-2020-40-5-390){ref-type="fig"}). The scores scatter plot ([Fig. 2A](#f2-alm-2020-40-5-390){ref-type="fig"}) generated using PCA analysis showed that the variables can be used to distinctively classify the two groups in an unbiased manner. The PLS-DA scores scatter plot indicated improved class separation ([Fig. 2B](#f2-alm-2020-40-5-390){ref-type="fig"}). As the PLS-DA model has an inherent bias towards classification, the model was validated for its overfitting tendency using permutation test statistics ([Fig. 2C](#f2-alm-2020-40-5-390){ref-type="fig"}). Our results indicate that the prediction capability of the original model is higher than that of the permutated models. The loading plot ([Fig. 2D](#f2-alm-2020-40-5-390){ref-type="fig"}) and variable importance plot (VIP; [Fig. 2E](#f2-alm-2020-40-5-390){ref-type="fig"}) generated from the PLS-DA analysis indicated that IL-10 was the most important variable responsible for the classification of endometriosis cases.

DISCUSSION
==========

Numerous studies have revealed disturbances in the immune response that are fundamental to the etiology and pathogenesis of endometriosis. The activation of NF-κB is principally regulated by ROS. Several rigorous studies have suggested the involvement of NF-κB transcriptional activity in endometriosis onset and progression \[[@b23-alm-2020-40-5-390], [@b24-alm-2020-40-5-390]\]. This is in agreement with our current findings that NF-κB expression is increased in patients with endometriosis than in controls ([Fig. 1](#f1-alm-2020-40-5-390){ref-type="fig"}). NF-κB is also known to induce several cytokines \[[@b25-alm-2020-40-5-390], [@b26-alm-2020-40-5-390]\]. It is evident that a selective block of NF-κB activation results in restricted communication and secretion of several pro-inflammatory cytokines, TNF-α, IL-6, and IL-8, which suggest the crucial role they play \[[@b27-alm-2020-40-5-390], [@b28-alm-2020-40-5-390]\]. Our results indicate a significant increase in the levels of pro-inflammatory cytokines, IL-1β, TNF-α, IFN-γ, and TGF-β1 in patients with endometriosis ([Table 2](#t2-alm-2020-40-5-390){ref-type="table"}). This finding is also supported by several previous studies reporting higher levels of pro-inflammatory cytokines in patients with endometriosis \[[@b13-alm-2020-40-5-390], [@b14-alm-2020-40-5-390], [@b16-alm-2020-40-5-390]\]. However, a few studies have reported decreased expression of IFN-γ \[[@b29-alm-2020-40-5-390], [@b30-alm-2020-40-5-390]\]. Increased levels of other cytokines, such as IL-2, IL-4, IL-6, IL-8, and IL-10, was also observed in patients with endometriosis ([Table 2](#t2-alm-2020-40-5-390){ref-type="table"}). These findings are in agreement with previous studies demonstrating an increase in the expression of these cytokines in serum and peritoneal fluid from patients with endometriosis \[[@b3-alm-2020-40-5-390], [@b16-alm-2020-40-5-390], [@b31-alm-2020-40-5-390]\].

Elevated expression of IL-10, a multifunctional cytokine, has been reported to play a major role in the establishment and maintenance of endometriosis \[[@b32-alm-2020-40-5-390]\]. This may be attributed to an increased level of pro-inflammatory cytokines such as IL-6 and TNF-α, which are known to induce IL-10 \[[@b33-alm-2020-40-5-390]\]. Previous studies have also demonstrated the overexpression of COX-2 in endometriosis \[[@b34-alm-2020-40-5-390]\]. This enzyme is pivotal in endometriotic cell survival, migration, and invasion, and its expression has been shown to be induced by the presence of TGF-β1 \[[@b35-alm-2020-40-5-390]\]. Our results indicated a significant increase in the expression of COX-2 in endometriosis. Furthermore, we also observed an increase in MMP-2 and −9 levels ([Table 2](#t2-alm-2020-40-5-390){ref-type="table"}), the activities of which are known to be regulated by COX-2 \[[@b36-alm-2020-40-5-390]\]. Moreover, decreased levels of TIMP-1 and −2 ([Table 2](#t2-alm-2020-40-5-390){ref-type="table"}) indicate an amplified MMP/TIMP ratio, which suggests an overall increase in ECM degradation in endometriotic women. Furthermore, the release of VEGF from the ECM is controlled by MMPs \[[@b37-alm-2020-40-5-390]\]; our results indicate that the elevated level of VEGF ([Table 2](#t2-alm-2020-40-5-390){ref-type="table"}) in patients with endometriosis promotes enhanced endometrial angiogenesis, which is reported to be an important factor for modulating endometriosis pathogenesis \[[@b38-alm-2020-40-5-390]\].

Multivariate statistical analysis was used to identify the most significant factor responsible for endometriosis pathogenesis. As evident from the PCA plot, the endometriosis and control groups are separated along with principal component 1 (t1) ([Fig. 2A](#f2-alm-2020-40-5-390){ref-type="fig"}). An improved class separation was observed in the PLS-DA scores scatter plot ([Fig. 2B](#f2-alm-2020-40-5-390){ref-type="fig"}). The loading plot ([Fig. 2D](#f2-alm-2020-40-5-390){ref-type="fig"}) and VIP ([Fig. 2E](#f2-alm-2020-40-5-390){ref-type="fig"}) generated from the PLS-DA analysis identified IL-10 as a significant variable capable of discriminating endometriosis samples from controls ([Fig. 2C](#f2-alm-2020-40-5-390){ref-type="fig"}).

In summary, we investigated changes in different molecular events during endometriosis onset and progression. We hypothesize that excessive OS induces NF-κB, which stimulates cellular processes leading to an increased level of cytokine production. In fact, NF-κB induces the T helper (Th)1 and Th2 response immune system in cases of pelvic endometriosis \[[@b39-alm-2020-40-5-390]\]. The Th1 immune response stimulates pro-inflammatory cytokines, whereas the Th2 immune response induces anti-inflammatory cytokines. In particular, IL-10 expression is increased in an attempt to balance the Th1/Th2 response \[[@b40-alm-2020-40-5-390]\]. Thus, we hypothesize that an overexpressed pro-inflammatory and anti-inflammatory cytokine response may increase endometriosis progression. Furthermore, higher expression of COX-2 during endometriosis may be attributed to the overexpression of anti-inflammatory cytokines. COX-2, in turn, up-regulates MMPs, leading to excessive ECM degradation. Additionally, reduced expression of TIMPs and imbalance between MMPs and TIMPs may increase ECM degradation. Excessive ECM degradation in conjunction with the impairment of cellular function may enhance the endometriotic lesion in an ectopic site for further disease progression. Although our results seem promising, elucidating the up- or down-regulation of these molecules in endometriosis is a complex issue and warrants further investigation with increased sample size. Further, a more localized investigation of these molecules in the peritoneal fluid and endometrial tissue is expected to provide a better understanding of the disease.
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![Flow cytometry analysis of NF-κB activation. (A) Percentage of cells with NF-κB (p50 and p65) activation as measured by flow cytometry. (B) Graphical representation of cells with NF-κB activation as measured by flow cytometry.\
Abbreviations: Cntrl, control; Endo, endometriosis.](alm-2020-40-5-390f1){#f1-alm-2020-40-5-390}

![Scores scatter plot of (A) PCA showing discrimination between endometriosis and controls, (B) PLS-DA showing improved discrimination between the two groups. (C) PLS-DA model cross-validation by permutation test statistics showing that the R2 (0.986) and Q2 (0.976) values of the original model are significantly greater than those of the 100 permutated models, indicating a good predictive ability. Variable extraction using (D) loading and (E) VIP plots showing that IL-10 is the most important variable for class separation.\
Abbreviations: PCA, principal-component analysis; PLS-DA, partial least square discriminate analysis; VIP, variable importance plot; IL, interleukin; TNF, tumor necrosis factor; IFN, interferon; TGF, transforming growth factor; VEGF, vascular endothelial growth factor; MMP, matrix metalloproteinase; TIMP, tissue inhibitor of metalloproteinase; COX, cyclooxygenase.](alm-2020-40-5-390f2){#f2-alm-2020-40-5-390}

###### 

Demographics of the patients recruited for the study

  Parameters                    Endometriosis[\*](#tfn1-alm-2020-40-5-390){ref-type="table-fn"}   Control[\*](#tfn1-alm-2020-40-5-390){ref-type="table-fn"}   *P*
  ----------------------------- ----------------------------------------------------------------- ----------------------------------------------------------- -------
  Age (yr)                      32.08±6.09                                                        30.43±4.39                                                  0.827
  BMI (kg/m^2^)                 28.24±0.78                                                        27.37±0.60                                                  0.379
  Serum estrogen level (ng/L)   228.10±12.08                                                      181.60±11.45                                                0.007

Values are presented as mean±SD.

Abbreviation: BMI, body mass index.

###### 

Levels of various cytokines, MMPs, TIMPs, COX-2, and VEGF in endometriosis patients and controls

  Parameters       Endometriosis[\*](#tfn3-alm-2020-40-5-390){ref-type="table-fn"}   Controls[\*](#tfn3-alm-2020-40-5-390){ref-type="table-fn"}   *P*
  ---------------- ----------------------------------------------------------------- ------------------------------------------------------------ ---------
  IL-1β (pg/mL)    18.28±3.69                                                        3.88±1.91                                                    \<0.001
  TNF-α (pg/mL)    117.43±20.73                                                      35.13±10.79                                                  \<0.001
  IFN-γ (pg/mL)    16.35±3.95                                                        4.48±2.42                                                    0.012
  TGF-β1 (pg/mL)   176.58±9.57                                                       110.84±6.64                                                  \<0.001
  IL-4 (pg/mL)     178.40±14.70                                                      77.00±16.39                                                  \<0.001
  IL-10 (pg/mL)    77.94±10.91                                                       18.73±2.67                                                   \<0.001
  IL-2 (pg/mL)     46.52±4.42                                                        18.79±2.20                                                   \<0.001
  IL-6 (pg/mL)     48.56±7.34                                                        15.61±4.33                                                   \<0.001
  IL-8 (pg/mL)     97.61±5.25                                                        51.45±8.38                                                   \<0.001
  VEGF (ng/mL)     546.93±23.99                                                      445.49±14.04                                                 \<0.001
  MMP-2 (ng/mL)    128.24±8.20                                                       86.43±2.13                                                   \<0.001
  MMP-9 (ng/mL)    154.12±8.75                                                       89.45±2.77                                                   \<0.001
  TIMP-1 (ng/mL)   33.58±7.13                                                        128.51±46.60                                                 \<0.001
  TIMP-2 (ng/mL)   30.71±3.09                                                        61.66±3.06                                                   \<0.001
  COX-2 (ng/mL)    7.36±0.78                                                         1.21±0.22                                                    \<0.001

Values are presented as mean±SD.

Abbreviations: IL, interleukin; TNF, tumor necrosis factor; IFN, interferon; TGF, transforming growth factor; VEGF, vascular endothelial growth factor; MMP, matrix metalloproteinase; TIMP, tissue inhibitor of metalloproteinase; COX, cyclooxygenase.
